Telmisartan induces a specific gut microbiota signature which may mediate its antiobesity effect. (August 2021)

• Record Type: Journal Article
• Authors: Beckmann, Laura; Künstner, Axel; Freschi, Marco L.; Huber, Gianna; Stölting, Ines; Ibrahim, Saleh M.; Hirose, Misa; Freitag, Miriam; Langan, Ewan A.; Matschl, Urte; Galuska, Christina E.; Fuchs, Beate; Knobloch, Johannes K.; Busch, Hauke; Raasch, Walter
• Is Part Of: Pharmacological research. Volume 170(2021)
• Publication Date: 2021-08
• Subjects: ACE2 Angiotensin I conversion enzyme type 2 -- Ang1-7 angiotensin (1-7) -- ARB angiotensin II receptor (type 1) blocker -- AUC area under the curve -- BF Brown-Forsythe ANOVA -- BMI body mass index -- bw body weight -- CD cafeteria diet -- CON control -- d day -- ET Enterotypes -- F/B ratio Firmicutes/Bacteroidetes ratio -- FER Food efficiency ratio -- FMT faecal microbiota transfer -- GIP glucose-dependent insulinotropic polypeptide -- GLP-1 glucagon-like-peptide-1 -- h hour -- HDL high-density lipoproteins -- HFD high-fat diet -- HOMA Homeostasis Model Assessment -- IL interleukin -- ITT insulin tolerance test -- KC keratinocyte chemoattractant -- LIX lipopolysaccharide-induced CXC chemokine -- min minute -- PBS phosphate-buffered saline -- PCR polymerase chain reaction -- PF pair-fed -- PP pancreatic polypeptide -- PYY peptide tyrosine tyrosine -- RAS renin-angiotensin system -- RER respiratory exchange ratio -- s.c. sub-cutaneous -- SCFA short-chain fatty acids -- SD standard deviation -- SD rats Sprague-Dawley rats -- sec second -- TEL the group of telmisartan-treated rats -- TG triglycerides -- w week; AT1-receptor antagonist -- Telmisartan -- Obesity -- Gut microbiota; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2021.105724
• Languages: English
• ISSNs: 1043-6618

Abstract

Abstract: Telmisartan prevents diet-induced obesity (DIO) in rodents. Given that the precise underlying mechanism is not known, we examined whether a gut-related mechanism might be involved. Sprague-Dawley rats received cafeteria diet (CD) for 3 months to develop DIO and were administered either telmisartan (8 mg/kgbw ) or vehicle. In addition, pair-fed (PF) rats received CD adjusted to TEL and control rats (CON) only received chow. Stool samples were analysed by 16 S rRNA gene amplicon sequencing. CD-fed rats became obese while TEL, PF and CON rats remained lean. Alpha diversity analyses indicated that bacterial diversity was similar before the study but changed over time. Beta diversity revealed a time-, CD- and telmisartan-dependent effect. The Firmicutes / Bacteroidetes ratio and the abundance of Blautia, Allobaculum and Parasutterella were higher in DIO and PF than in CON, but not in TEL. Enterotype (ET)-like clustering analyses, Kleinberg's hub network scoring and random forest analyses also indicated that telmisartan induced a specific signature of gut microbiota. In response to stool transfer from telmisartan-pre-treated donor to high-fat fed acceptor mice, body weight gain was slightly attenuated. We attribute the anti-obesity action of telmisartan treatment to diet-independent alterations in gut microbiota as the microbiota from telmisartan-treated, CD-fed rats clearly differed from those of DIO and PF rats. ET-like clustering network, random forest classification and the higher stability in bacterial co-occurrence network analyses indicate that there is more than one indicator species for telmisartan's specific signature, which is further strengthened by the fact that we cannot identify a single indicator species. Graphical Abstract: ga1 Highlights: Cafeteria diet-fed rats became obese while telmisartan-treated rats remained lean. Firmicutes / Bacteroidetes ratio, beta diversity, and BORAL analysis and heatmap indicated changes in microbiota when rats received cafeteria diet whereas additional telmisartan treatment stabilized microbiota on the control pattern. The anti-obesity effects of AT1 -receptor antagonists might be attributable to diet-independent alterations in the gut microbiota.